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Abstract
Purpose The fracture stage of non-traumatic osteonecrosis
(ON stage 3) of the femoral head (ONFH) has an unfavourable
prognosis frequently requiring total hip replacement (THR).
The percentage could be lowered after core decompression. In
earlier non-fracture ON stages, implantation of autologous
bone marrow aspirate concentrate (BMAC) improved the ef-
fect of core decompression. The purpose was to evaluate the
effect of BMAC in addition to core decompression in stage 3
ONFH.
Methods A double blind RCTwas conducted comparing two
groups: core decompression plus saline injection or core de-
compression plus BMAC implantation. Both patients and as-
sessors were blinded to the treatment assignments.
Evaluations were done at baseline, three, six, 12, and
24 months, including pain (VAS), WOMAC, side-effects, ra-
diological evolution including ARCO subclassifications, to-
gether with possible THR requirement. The primary endpoint
was the need for THR. The second endpoints included the
clinical symptoms such as pain and functional ability and
the progression of the ON lesions as well as the appearance
of osteoarthritis features (ARCO stage 4). Both groups includ-
ed 23 hips (19 patients).
Results No differences were found between the groups for
THR requirements, clinical tests, and radiological evolution.
In both groups, 15/23 hips needed THR. The radiological
evolution of the ONFH lesions in term of location, extension,
surface collapse, and dome depression was moderate in both
groups and was not correlated with the need of THR.
Conclusions Implantation of BMAC after core decompres-
sion did not produce any improvement of the evolution of
ONFH stage 3.
Level of evidence I.
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Introduction
Aseptic non-traumatic osteonecrosis of the femoral head
(ONFH) is a painful disorder which leads in 80% of cases to
a total hip replacement (THR) [1]. Glucocorticoids and alco-
hol abuse are the most frequent risk factors for ONFH in
Caucasians [2].
The treatment of ONFH, particularly in fracture stages,
remains challenging. Two specific features of ONFH empha-
size the importance of developing a conservative surgical ther-
apeutic approach since prosthetic replacements rarely last for
their lifetime and could be required for more than one joint.
Firstly, patients suffering from ONFH are young. In a recent
ONFH cohort study the mean age was 48.4 years with the
youngest being 19 years old [3]. Secondly, patients suffering
from ONFH have a high risk of multiple surgical procedures.
Indeed, multiple ON lesions are frequent: bilateral lesions
were found in 63% of the patients and 11% had multifocal
ON (more than 2 ON sites) [3]. Core decompression of the
femoral head is the most widespread conservative surgical
procedure proposed to treat ONFH. Although this procedure
has already been employed for more than five decades [4], its
efficacy remains controversial [5, 6]. The success rate for core
decompression is even worse when a subchondral fracture
(47% in ARCO stage 3) is present compared to the pre-
collapse stages (85% in ARCO stage 1 and 65% in ARCO
stage 2) [1, 7].
Recent publications suggested that ON might be a dis-
ease of bone cells and mesenchymal stem cells (MSC) [8,
9]. The activity levels together with the number of MSC in
the bone marrow is depressed in patients with ONFH [8].
The replication capacity of osteoblastic cells is decreased in
the proximal femur of patients with ONFH [9]. The apopto-
sis of osteoblasts and osteocytes is increased especially in
the so-called creeping substitution surrounding the necrotic
region [10]. These findings raised the possibility that bone
marrow containing MSC implanted into the necrotic lesion
of the femoral head could be useful. A two year prospective
controlled study showed that, in unfractured ONFH cases,
the implantation of autologous bone marrow aspirate con-
centrate (BMAC) into the necrotic lesion through a core
decompression procedure was more effective than core de-
compression alone in improving pain and hip function and
reducing the number of hips that progressed to subchondral
fracture [11]. The course of the disease over 24 months was
deemed satisfactory in 90% of the hips in the BMAC group
compared to 37.5% in the control group. This positive effect
was confirmed in a five year follow-up study [12].
The natural evolution of ON stage 3 seems poor, with 87%
of cases requiring THR, which may be reduced to 53% after
core decompression [1]. A beneficial effect — reduction of
both functional evolution and need for THR— has also been
reported in fracture ONFH [13]. The purpose of the present
study was, therefore, to evaluate the effect of the addition of
BMAC implanted in the necrotic lesion in comparisonn with a
core decompression alone in ARCO stage 3 ONFH. We initi-
ated a randomized controlled trial (RCT) on the effect of
BMAC implantation into the necrotic lesion of fracture stages
ONFH using the same technique as previously described [14].
Patients and methods
The study was conducted in two university centers: Hôpital
Erasme, Université de Bruxelles and CHU de Liège,
University of Liège. Osteonecrosis was diagnosed by X-rays
and MRI for each case [15]. The ON staging used was the
ARCO classification system using X-rays and MRI [16, 21].
The primary objective was to confirm, in ARCO stage 3
ONFH, the BMAC injection’s effect on the need for a THR.
The secondary objectives were to evaluate the advantage
produced by BMAC concerning pain, functional ability, pro-
gression of ON lesions in terms of location, extension, surface
collapse, dome depression evolution, and appearance of oste-
oarthritis features (evolution to ARCO stage 4).
The inclusion criteria were patients aged 18 years or older
suffering from ARCO stage 3 non-traumatic ONFH with a
surface collapse lower than 30% of the entire articular surface
together with a dome depression of no more than 4 mm, and
who had signed the written consent form. The exclusion
criteria were evidence of malignant disorder in the past
five years, contraindication to undergo an MRI, or a positive
serological test for HIV, hepatitis B or hepatitis C.
Randomization
A centralized assignment to treatment groups was performed
for the two centres. The subject under investigation was pa-
tient’s hip. We therefore randomly allocated hips to a core
decompression procedure associated with BMAC implanta-
tion (BMAC group) or saline implantation (control group).
In case of eligibility, hips were allocated through a randomi-
zation process to one of the two study arms, with a ratio 1:1. A
randomization list was generated, using random permuted
blocks of two letters. Randomization was adapted for bilateral
lesions because the bone marrow aspiration volume had to be
limited for ethical reasons andMSC numbers decrease in larg-
er bone marrow collection volumes [17] When the two hips
(of the same patient) affected with ONFH were enrolled in the
study, the right hip was assigned to the treatment arm from the
first available envelop. The other hip was then assigned to the
other treatment arm, using the next available envelop with said
assignment, in order to ensure exactly equal treatment num-
bers as specified in the randomization code.
As proof-of-concept study, an optimal sample size was
impossible to calculate. No formal sample size calculation
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was performed. Sixty subjects (hips) were planned to be en-
rolled. This number was considered sufficient to document the
efficacy and safety.
This study was a double-bind study: participants and out-
come assessor (clinicians and radiologists) were unaware of
which treatment assignment was which. Treating clinicians
were not masked to treatment assignment.
Core decompression and BMAC procedures
The procedures were previously published [14, 18]. Under
general anaesthesia, a volume of 400 mL of bone marrow
was harvested from the posterior iliac crests and was sorted
on a Spectra cell separator (777,006,300; Cobe, Lakewood,
Colorado) and concentrated to a final volume of 50ml. During
the same general anaesthesia, a special 4 mm trephine was
inserted under control of a fluoroscopic view through the great
trochanter, the neck, and the femoral head in the necrotic le-
sion. Then the BMAC (BMAC group) or saline 50 ml (control
group) was injected into the necrotic region. To avoid any
leakage, a Gelfoam® absorbable gelatin sponge (Pharmacia
& Upjohn Company, Kalamazoo, MI 49001, USA) was
pushed through the trephine to close the hole. In the control
group, a sham skin incision was done at the site of bone mar-
row harvesting. So, the patients were unaware of the treatment
received.
Clinical evaluation
Two investigators, unaware of the treatment group assign-
ments, performed all the post-operative outcome assessments.
Patients were assessed at baseline, three, six, 12, and
24 months. Patients’ assessments of pain included a visual
analogue scale (VAS) from 0 mm (no pain) to 100 mm (severe
pain) [19]. Symptoms were also assessed by the subscales A
and B (both dedicated to the hip status) of the WOMAC score
[20]. In the case of hip bilateral involvement, patients were
asked to complete a separate questionnaire for each hip.
During each visit, safety was assessed by recording adverse
events and serious adverse events. The decision to possibly
turn to THR when the treatment had been insufficient in con-
trolling pain and/or disability, was discussed with the patient
at the end of each assessment session. The final decision was
taken according to the patient’s own wishes.
Radiological evaluation
Anteroposterior and frog leg view weight-bearing radiographs
and an MRI study were taken at baseline, three, six, 12, 18,
and 24 months. Radiological progression of ONFH was mea-
sured by reference to the ARCO staging [16, 21] For location
and quantification of ON lesion, the ARCO subclassifications
were used [16, 21]. The location of the ON lesion under a
weight-bearing dome of the acetabulum was A = medial,
B = central, C = lateral; the extension of the lesion (a calcula-
tion of the area of femoral head involvement) was: A = < 15%,
B = 15–30%, C = > 30%. The surface collapse extension was,
after selection of the most prominent view, expressed as a
percentage of the entire articular surface: A = < 15% involve-
ment, B = 15–30% involvement, C = > 30% involvement. The
dome depression was expressed as A = a depression of less
than 2 mm, B = 2–4 mm, and C = more than 4 mm. A single
reader, unaware of the treatment assignments, analyzed all
radiographs and MRI.
Statistical methods
Continuous variables were given by their mean ± SEM; their
means were compared between two independent groups with
Student t-tests, or with Welch tests in the case of variance
heterogeneity. Qualitative variables were given by their pro-
portions and were compared between independent groups
with Fisher’s exact chi-square tests.
All statistical analyses were performed using the statistical
software IBM-SPSS-V22.0. A statistically significant effect
was considered as soon as the p-value was lower than 0.05.
Results
The cohort formation is summarized in the CONSORT flow
diagram (Fig. 1). We screened 60 hips from 46 patients (14
patients with bilateral stage 3 ON). We could randomize 52
hips/42 patients (ten with bilateral stage 3 ON) in the two
groups. Finally, we were able to evaluate 23 hips from 19
patients (eight with bilateral stage 3 ON) in the BMAC group
and 23 hips from 19 patients (eight with bilateral stage 3 ON)
in the control group.
The baseline demographic characteristics are presented in
Table 1. No statistical differences between both groups were
found in terms of gender, age, BMI, side of unilateral ON,
duration of symptoms, bilateral and multifocal ON presenta-
tions, risk factors, pain, and WOMAC scoring. The hips
displayed similar fracture ARCO stage 3 ONFH in terms of
location and extension of ON lesions, surface collapse, and
dome depression.
TheBMAChad a final volume of 48.33 ± 1.16ml. Themean
number of nucleated cells injected was 3.46 ± 0.36 × 109 includ-
ing 1.5 ± 0.28%CD34+. Themean number of Fibroblast colony
forming units (CFU-F) was 19.45 ± 3.51 × 106 nucleated cells.
At the 24-month follow-up, no difference was found be-
tween groups of either the primary or secondary endpoints
(Table 2).
The primary objective was to confirm the effect of BMAC
on the need for a THR. In the BMAC group 15 hips and in the
control group 23 hips needed a THR (p = 1.000). The time to
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Assessed for eligibility: n=60 (46) 
Excluded: n=8 (4) 
♦ Not meeting inclusion criteria: n= 2 (1) 
♦ Declined to participate: n=6 (3)
Analysed: n=23 (19) 
♦ Excluded from analysis (n=0)
Lost to follow-up: n=1 (1) (consent withdrawal) 
Allocated to control group: n=26 (21) 
♦ Received allocated intervention: n=24 (20)
♦ Did not receive allocated intervention: n=2 (1) 
(consent withdrawal)
Lost to follow-up: n=1(1) (consent withdrawal) 
Allocated to BMAC group: n=26 (21) 
♦ Received allocated intervention: n=24 (20)
♦ Did not receive allocated intervention: n=2 (1) 
(consent withdrawal)
Analysed: n=23 (19) 
♦ Excluded from analysis (n=0)
Randomized: n=52 (42) 
Fig. 1 CONSORT flow diagram
for stage 3 ONFH BMAC versus
core trial: hips (patients)
Table 1 Baseline demographic
data and characteristics of ONFH Control group BMAC group p-value
N of evaluable patients 19 19
Bilateral inclusions (patients) 4 4
Male (unilateral/bilateral) 13 (10/3) 14 (11/3) 1.000
Female (unilateral/bilateral) 6 (5/1) 5 (5/1) 1.000
Age (years) 49.7 ± 3.2 48.0 ± 2.8 0.673
BMI 24.53 ± 0.96 25.35 ± 0.75 0.469
N of evaluable hips 23 23
ON lesions unilateral/bilateral/multifocal 7/15/1 7/16/0 0.740
Hip side (right/left) 14/9 7/16 0.068
Duration of symptoms (months) 6.7 ± 1.2 6.3 ± 0.6 0.758
Risk factors 0.350
Corticosteroids use 13 12
Alcohol abuse 7 8
Drepanocytosis 0 2
Idiopathic 3 1
Pain VAS (mm) 46.7 ± 5.7 58.4 ± 4.5 0.555
WOMAC A score 7.1 ± 1.1 7.7 ± 0.6 0.972
WOMAC B score 3.8 ± 0.5 3.2 ± 0.4 0.512
ON location (A/B/C) 4/9/10 2/10/11 0.717
ON extension (A/B/C) 3/4/16 2/3/18 0.878
Surface collapse (A/B/C) 19/4/0 22/1/0 0.176
Dome depression (A/B/C) 18/5/0 21/2/0 0.403
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THR was 9.7 ± 1.2 months for the BMAC group and
8.2 ± 0.8 months for the control group (p = 0.382).
The secondary objectives were to evaluate the advantage
produced by BMAC concerning pain, functional ability,
progression of ON lesions in terms of location, extension,
surface collapse, dome depression evolution, and appear-
ance of osteoarthritis features (evolution to ARCO stage 4).
No significant improvement of pain (VAS) or functional
ability (WOMAC subscales A and B) was found in the
BMAC group. An evolution to stage 4 was noted in ten hips
(43%) in the BMAC group after 9.9 ± 2.6 months and nine
hips (43%) in the control group after 9.3 ± 2.2 months
(p = 0.871). The ON lesions were only increased in a few
hips (Table 2). Concerning the quantification of the ON
lesions in the BMAC group versus control group, ON loca-
tion was worsened in two hips (9%) versus one (5%), ex-
tension in one hip (5%) versus one hip (5%), surface col-
lapse in ten hips (43%) versus eight hips (38%), and dome
depression in seven hips (30%) versus six hips (29%).
These ON lesion evolutions showed no statistical differ-
ence between the two groups (p-values between 0.637 and
1.000) and were not related to the need of THR (p = 1.000).
The survey of potential side effects did not reveal any se-
rious adverse event. Few adverse events were reported: pain at
the great trochanter in four cases (one in the BMAC group)
and at the iliac crest in two (two in the BMAC group), fever
for less than 24 hours with negative bacteriological investiga-
tions in two cases in the BMAC group and nausea in two cases
(one in the BMAC group).
Discussion
Our RCT has not confirmed the advantage of BMAC implan-
tation in comparison with core decompression alone in ON
stage 3. No statistically significant difference has been ob-
served between the core decompression plus saline injection
(control group) and the core decompression plus BMAC (im-
plantation group) concerning the need for a THR, the evolu-
tion of pain and functional ability, the evolution of the necrotic
lesion, and the appearance of osteoarthritis.
A review of the available literature revealed that no other
RCT evaluating the effect of BMAC implantation or other
cell-based treatments in stage 3 ONFH was published. We
Table 2 Results (hips)
Control group BMAC group p- value
N hips 23 23
THR 15 15 1.000
Time to THR (month) 8.2 (2–12) 9.7 (6–22) 0.382
THR in bilateral ON yes/no 7/1 (stage 4) 7/1 (stage 4) 1.000
Evolution to stage 4 9 10 1.000
Time to stage 4 (month) 9.3 (3–24) 9.9 (3.24) 0.871
To stage 4 without arthroplasty 3 4 1.000
Pain VAS evolution −2.3 ± 6.4 −7.7 ± 5.9 0.853
WOMAC A score evolution −0.6 ± 0.9 −1.5 ± 1.0 0.678
WOMAC B score evolution −0.1 ± 0.4 −1.5 ± 1.3 0.505
ON location evolution A→ B/A→ C/B→ C 0/1/0 0/0/2 0.637
ON extension evolution A→ B/A→ C/B→ C 0/0/1 0/1/0 1.000
Surface collapse evolution A→ B/A→ C/B→ C 5/3/0 6/4/0 1.000
Dome depression evolution A→ B/A→ C/B→ C 3/3/0 3/1/3 1.000
Evolution = difference between the baseline and the last values (24 months or THR timing)
Table 3 Trials including stage 3
ONFH treated by core plus
BMAc (see text)
Present study Hernigou ref [13] Wang ref [23] Yoshioka ref [24]
Trial design RCT Retrospective Open prospective Retrospective
Intervention Mini-core Mini-core 2–3 mini-core Mini-core
N° hip 46 44 9 9
Staging system ARCO Steinberg ARCO Japan Orthop Assoc
FU duration (month) 24 92 28 41
THR 65% 42% 11% 33%
RCT = randomized controlled trial. THR = total hip replacement. Mini core = core with 3.5 to 5 mm outer
diameter trephine
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only found publications where fractured ONFH were only a
part of the studied cases (Table 3). Hernigou et al. reported a
cohort study of ONFH treated with the same protocol as the
one we used: mini core decompression and BMAC implanta-
tion in the necrotic area [13]. In this study, ON Steinberg
stages 3 (no flattening of more than 1 mm) and 4 (flattening
of more than 1 mm without joint narrowing) were similar to
our ON population although the definition of the staging was
slightly different because we used the ARCO reference (no
flattening more than 4 mm). A second difference was the
follow-up duration: more than five years in the Hernigou
study versus two years in our study. Arthroplasty was needed
in 5/12 ON stage 3 (42%), and, in our study, in 15/23 hips
(65%). Some differences were found concerning the
aetiological factors: more cases having alcohol abuse and
sickle cell disease were present than in our study in which
more patients had received corticosteroids. However, sickle
cell disease seems to confer a worse ON prognosis [22]. So,
the differences remained inexplicable. In another publication,
a cohort study of BMAC treatment in ON included nine
ARCO stage 3A ONFH with a follow-up of 27, six months
[23]. The radiological progression occurred in 33, 3% and
only 1/9 required a THR. Finally, a retrospective study
reporting nine hips in six SLE patients treated with corticoids
included three Japanese orthopaedic stage 3 ONFH [24]. After
a minimum follow-up of three years, 1/3 hips had a radiolog-
ical worsening and a THR requirement. These results are bet-
ter than those of our study, but they are vitiated by some
weaknesses: no control group and retrospective case reports.
Some limitations also exist in our study: many drop out
reducing the studied cohort, the lack of sample size calcula-
tion, and the inclusion of bilateral ONFH. Absence of statis-
tical effect does not however mean no effect as this could be
attributed to too small sample sizes, but nevertheless no trend
toward any difference was detected. So the rationale for fur-
ther increasing the sample sizes has not been estimated rele-
vant notably taking into account the difficulty of gathering the
required patient’s data.
Further regenerative therapy programs, using the RCT
methodology, should further assess the therapeutic values of
such programs including cell implantation, growth factors,
and scaffolds.
In our study, the evolution of the ON lesions (exten-
sion, worsening of the subchondral bone collapse, evolu-
tion to osteoarthritis) was not correlated to the need of
THR. In both groups the worsening of ON was very lim-
ited (Table 3). In ONFH, the need for THR could be
related not only to a worsening of the collapse but also
to other factors such as synovitis, cartilage lesions, or
periarticular disturbances. Interestingly, a therapeutic ap-
proach of ONFH dedicated to mechanical stabilization of
the collapse by cementation was ineffective [25]. A more
precise analysis of lesion size based on the MRIs would
confirm this lack of relationship between clinical failure
and worsening of the bone collapse.
In conclusion, our study did not find any significant im-
provement of ON evolution in stage 3 ONFH when BMAC
implantation in the necrosis is added to core decompression.
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